621 
Stochastic Evolution of Drug-resistant Strains of HIV in Botswana
Raffaele Vardavas* and S Blower
David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US
Background: Approximately 40% of adults in Botswana are
HIV-infected. The Botswana ART program began in 2002 and currently treats
34,000 patients with a goal of treating 85,000 patients (~30% of HIV-infected
adults) by 2009. We predict the stochastic evolution of drug-resistant strains
of HIV that may emerge as a consequence of this treatment program.
Specifically, we predict the magnitude and temporal dynamics of the evolution
of transmitted drug-resistant strains. We discuss the implications of our results
in the context of the World Health Organization’s (WHO’s) proposed surveillance
system for detecting drug-resistant strains of HIV in Africa.
Methods: We present a novel stochastic dynamic
model of the emergence and evolutionary dynamics of drug resistance. We use our
model to formulate a birth-death-immigration master equation, and use this
equation to obtain an analytical solution of probabilistic evolutionary trajectories.
We incorporate demographic and treatment data into our model to make specific
predictions for Botswana.
Results: Our stochastic evolutionary trajectories
show that, even if rates of acquired resistance are high, but the drug-resistant
strains that evolve are only half as fit (i.e., transmissible) as wild type
strains, then transmission of these drug-resistant strains would remain low
(<5% by 2009) and would likely be undetectable by the WHO’s surveillance
system. However, our stochastic evolutionary trajectories show that transmission
of drug-resistant strains in Botswana
could increase to ~15% by 2009 if the resistant strains are as fit as wild type
strains.
Conclusions: The WHO’s surveillance system is designed
to detect transmitted resistance that exceed a threshold level of 5%. Whether
this system will detect drug-resistant strains in Botswana by 2009 will depend upon
the fitness of the strains that evolve. Our results imply that it will be many
years before the WHO will detect transmitted resistance in other sub-Saharan
African countries with less ambitious treatment programs than Botswana.
|